Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-01-17
2006-01-17
Maier, Leigh C. (Department: 1623)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
C562S500000, C562S501000, C562S553000, C562S556000, C568S374000
Reexamination Certificate
active
06987193
ABSTRACT:
The present invention provides illudin analogs of the general formula (I):where R1is (CH2)n—X—Y or H; n is 0 to 4; X is O or S or N or absent; and Y is an optionally substituted (C1-C8)alkyl, (C6-C10)aryl, (C6-C10)aryl(C1-C4)alkyl or cyclo(C3-C6)alkyl optionally comprising one or more heteroatoms; a monosaccharide, an amino acid residue, or H when n is 2-4;R2is absent; or R1and R2together comprise a 5-7 membered cyclic ring;R3is (C1-C4)alkyl or H; R4is H, SCH2CO2(C1-C4)alkyl, O—(C5-C12)aryl or —S—(C5-C12)aryl; R5is H, OH or absent; R6is (C1-C4)alkyl or absent; R7is OH or OSi((C1-C4)alkyl)3; orR6and R7together are ethylenedioxy;R8is optionally substituted (C1-C4)alkyl; andthe bonds represented by ----- are individually present or absent. The invention further provides dimers comprising analogs of formula (I).
REFERENCES:
patent: 4559157 (1985-12-01), Smith et al.
patent: 4608392 (1986-08-01), Jacquet et al.
patent: 4612302 (1986-09-01), Szabo et al.
patent: 4684620 (1987-08-01), Hruby et al.
patent: 4820508 (1989-04-01), Wortzman
patent: 4853371 (1989-08-01), Coy et al.
patent: 4938949 (1990-07-01), Borch et al.
patent: 4992478 (1991-02-01), Geria
patent: 5387578 (1995-02-01), Angelucci et al.
patent: 5439936 (1995-08-01), Kelner et al.
patent: 5439942 (1995-08-01), Kelner et al.
patent: 5523490 (1996-06-01), Kelner et al.
patent: 5563176 (1996-10-01), Kelner et al.
patent: 5723632 (1998-03-01), McMorris
patent: 5932553 (1999-08-01), McMorris et al.
patent: 6025328 (2000-02-01), McMorris et al.
patent: 6069283 (2000-05-01), McMorris et al.
patent: 6380403 (2002-04-01), McMorris et al.
patent: 6639105 (2003-10-01), McMorris et al.
patent: 0915819 (2004-05-01), None
patent: 208115 (1991-05-01), None
patent: 62-234040 (1987-10-01), None
patent: WO-91/04754 (1991-04-01), None
patent: WO-9104754 (1991-04-01), None
patent: WO-WO91/04754 (1991-04-01), None
patent: WO-94/18151 (1994-08-01), None
patent: WO-94/25013 (1994-11-01), None
patent: WO-96/34005 (1996-10-01), None
patent: WO-97/03995 (1997-02-01), None
patent: WO-98/03458 (1998-01-01), None
Kelner, M. et al. “In vitro and in vivo studies on the anticancer activity of dehydroilludin M” Anticancer Res. (1995) vol. 15, pp 873-878.
McMorris, T. et al “(Hydroxymethyl)acylfulvene: an illudin derivative with superior antitumor propertiesa”, J. Nat. Prod. (1996) vol. 59, pp 896-899.
McMorris, T. et al “An acetal derivative of illudin S with improved antitumor activity” Tet. Lett. (1997) vol. 38, No. 10, pp 1697-1698.
European Search Report from European Application No. 04 01 2220, dated Jul. 15, 2004, 5 pgs.
Anchel, Marjorie , et al., “Antibiotic Substances From Basidiomycetes. VII. Clitocybe Illudens”,Proceedings of the National Academy of Sciences, 36(5), (1950),300-305.
Anchel, M. , et al., “The Biogenesis of Illudins S and M in Clitocybe Illudens”,Phytochemistry, 9(11), (Nov. 1970),2339-2343.
Arap, Wadih , et al., “Cancer Treatment by Targeted Drug Delivery to Tumor Vasculature in a Mouse Model”,Science, 279(5349), (Jan. 16, 1998),377-380.
Brandsteterova, E. , et al., “HPLC Analysis of Novel Anti-Cancer Agents-Illudens and Their Analogs”,Journal of Liquid Chromatography, 16(1), (1993),pp. 115-125.
Brandsteterova, E. , et al., “HPLC Determination of a New Anticancer Agent (Acylfulvene) in Serum”,Neoplasma, 39(6), (1992),pp. 369-373.
Burres, N. S., et al., “Antitumor Activity and Mechanism of Action of the Novel Marine Natural Products Mycalamide-A and -B and Onnamide”,Cancer Research, 49, (Jun. 1989),2935-2940.
Curtis, Erin A., et al., “An Efficient Dipolar-Cycloaddition Route to the Pterosin Family of Sesquiterpenes”,Tetrahedron Letters, 36(12), (Mar. 1995),pp. 1989-1992.
Dillman, R. O., et al., “Athymic Mouse Model of a Human T-Cell Tumor”,Cancer Research, 45, (Nov., 1985),pp. 5632-5636.
NG, K. M., et al., “An Efficient Synthesis of Pterosin C and Other Pterosins”,Canadian Journal of Chemistry, 62(10), (Oct. 1984),pp. 1945-1953.
French, A. L., et al., “Poisoning with the North American Jack O' Lantern Mushroom”,Clinical Toxicology, 26(1&2), (1988),pp. 81-88.
Giovanella, B. C., et al., “Correlation Between Response to Chemotherapy of Human Tumors in Patients and in Nude Mice”,Cancer, 52, (1983),pp. 1146-1152.
Giovanella, B. C., et al., “DNA Topoisomerase I-Targeted Chemotherapy of Human Colon Cancer in Xenografts”,Science, 246(4933) (Nov. 24, 1989),pp. 1046-1048.
Goldin, A. , et al., “Current Results of the Screening Program at the Division of Cancer treatment, National Cancer Institute”,Europ. J. Cancer, 17, (1981),pp. 129-142.
Goldin, A. , et al., “Historical Development and Current Strategy of the National Cancer Institute Drug Development Program”,In: Methods in Cancer Research, vol. XVI, Cancer Drug Development Part A, Chapter V, Academic Press, Inc., New York,(1979),pp. 165-245.
Greene, T. W.,Protective Groups in Organic Synthesis, Chapters 4, 5&6, John Wiley & Sons, Inc., New York,(1981),pp. 114-217.
Hanson, J. R., et al., “Studies in Terpenoid Biosynthesis, Part XV. Biosynthesis of the Sesquiterpenoid Illuden M”,Journal of the Chemical Society, Perkin Transactions I,(1976),876-880.
Hara, M. , et al., “6-Deoxyilludin M, a New Antitumor Antibiotic: Fermentation, Isolation and Structural Identification”,The Journal of Antibiotics, 40, (Nov. 1987),pp. 1643-1646.
Harttig, U. , et al., “Leaianafulvene, a Sesquiterpenoid Fulvene Derivative from Cultures of Mycana Leaiana”,Phytochemistry, 29(12), (1990),pp. 3942-3944.
Hirono, O. , et al., “Reproduction of Acute Bracken Poisoning in a Calf with Ptaquiloside, a Bracken Constituent”,The Veterinary Record, 115(15), (Oct. 1984),pp. 375-378.
Inoue, K. , et al., “Antitumor Efficacy of Seventeen Anticancer Drugs in Human Breast Cancer Xenograft (MX-1) Transplanted in Nude Mice”,Cancer Chemother. Pharmacol., 10, (1983),pp. 182-186.
Kawato, Y. , et al., “Antitumor Activity of a Carnptothecin Derivative, CPT-11, Against Human Tumor Xenografts in Nude Mice”,Cancer Chemother, Pharmacol., 28, (1991),pp. 192-198.
Kelner, M. J., et al., “Nonresponsiveness of the Metastatic Human Lung Carcinoma MV522 Xenograft to Conventional Anticancer Agents”,Anticancer Research, 15, (1995),pp. 867-872.
Kelner, M. J., et al., “Preclinical Evaluation of Illudens as Anticancer Agents”,Cancer Research, 47, (1987),pp. 3186-3189.
Kelner, M. J., et al., “Preclinical Evaluation of Illudens as Anticancer Agents: Basis for Selective Cytotoxicity”,J. Natl. Cancer Inst., 82(19), (1987),pp. 1562-1565.
Lu, Jianliang , et al., “An expeditious synthesis of the potent antitumor agent, (+)-hydroxymethylacylfulvene using an allenic Paulson-Khand type cycloaddition”,American Chemical Society, Division of Organic Chemistry Abstracts, 217th ACS National Meeting in Anaheim, CA,(Mar. 21-25, 1999), 1 p.
Matsumoto, Takeshi , et al., “An Alternative Synthesis of Illudin M”,Tetrahedron Letters, 14, (Mar. 1970),pp. 1171-1174.
Matsumoto, T. , et al., “Synthesis of Illudin S”,Tetrahedron Letters, 23, (May 1971),pp. 2049-2052.
McMorris, T. C., et al., “(Hydroxymethyl)acylfulvene: An Illudin Derivative with Superior Antitumor Properties”,Chemical Abstracts, abstract No. 196032, vol. 125, No. 15,(Oct. 7, 1996).
McMorris, T. C., et al., “Acylfulvenes, a New Class of Potent Antitumor Agents”, 52(1), Deptl. of Chemistry and Pathology; University California,(1996),75-80, Experientia.
McMorris, Trevor C., et al., “An Acetal Derivative of Illudin S with Improved Antitumor Activity”,Tetrahedron letters, 38(10), (1997),pp. 1697-1698.
McMorris, T. C., et al., “Design and Synthesis of Antitumor Acylfulvenes”, 62 (9), Deptt. of Chemistry and Biochemistr
Kelner Michael J.
McMorris Trevor C.
Maier Leigh C.
The Regents of the University of California
LandOfFree
Illudin analogs useful as antitumor agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Illudin analogs useful as antitumor agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Illudin analogs useful as antitumor agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3574772